Українська English

ISSN 2522-9028 (Print)
ISSN 2522-9036 (Online)

Fiziologichnyi Zhurnal

is a scientific journal issued by the

Bogomoletz Institute of Physiology
National Academy of Sciences of Ukraine

Editor-in-chief: V.F. Sagach

The journal was founded in 1955 as
1955 – 1977 "Fiziolohichnyi zhurnal" (ISSN 0015 – 3311)
1978 – 1993 "Fiziologicheskii zhurnal" (ISSN 0201 – 8489)
1994 – 2016 "Fiziolohichnyi zhurnal" (ISSN 0201 – 8489)
2017 – "Fiziolohichnyi zhurnal" (ISSN 2522-9028)

Fiziol. Zh. 2017; 63(6): 39-46


A. Goryachyi, Yu.Karpenko, E. Levchenko, O. Gozhenko, A. Gozhenko

    Ukrainian Research Institute of Transport Medicine; Odessa Regional Clinical Hospital, Ukraine


In this work, the content of matrix metalloproteinase-9 (MMP-9) in the blood serum was studied as an independent predictor of recurrence of atrial fibrillation after catheter radiofrequency ablation (CRA). The results of analyzes of patients with long-persistent form of atrial fibrillation (LPAF) lasting more than one year and resistant to drug therapy are analyzed. All patients before the procedure of catheter radiofrequency ablation measured the concentration of MMP-9 and evaluated its association with the recurrence of arrhythmias at the end of the postoperative period. For this, enzyme-linked dual enzyme immunoassay was used. 35 patients with LPAF were examined. The follow-up period was 16.2 + 5.7 months, in 12 (34.3%) patients there was a relapse of the arrhythmia after the ablation procedure. The basic content of MMP-9 was higher in patients with relapsed arrhythmia (261.3 + 35.3 and 202.46 + 27.6 ng/ml, respectively, P <0.05). Multivariate analysis showed that parameters such as MMP-9 content, a history of atrial fibrillation and a diameter of the left atrium were independent predictors of arrhythmia recurrence. Thus, MMP-9 is an independent predictor of arrhythmia recurrence after performing the procedure of catheter radiofrequency ablation in patients with atrial fibrillation.

Keywords: remodeling; matrix metalloproteinases; atrial fibrillation, catheter ablation


  1. Pappone C, Vicedomini G, Augello G, Manguso F, Saviano M, Baldi M, et al. Radiofrequency catheter ablation and antiarrhythmic drug therapy: a prospective, randomized, 4-year follow-up trial: the APAF study. Circ Arrhythm Electrophysiol. 2011;4(6):808-14. CrossRef PubMed
  3. Elayi CS, Verma A, Di Biase L, Ching CK, Patel D, Barrett C, et al. Ablation for longstanding permanent atrial fibrillation: results from a randomized study comparing three different strategies. Heart Rhythm. 2008;5(12):1658-64. CrossRef PubMed
  5. Sanders P, Hocini M, Jais P, Sacher F, Hsu LF, Takahashi Y et al. Complete isolation of the pulmonary veins and posterior left atrium in chronic atrial fibrillation. Longterm clinical outcome. Eur Heart J. 2007;28(15):1862-71. CrossRef PubMed
  7. Tilz RR, Rillig A, Thum AM, Arya A, Wohlmuth P, Metzner A, et al. Catheter ablation of long-standing persistent atrial fibrillation: 5-year outcomes of the Hamburg Sequential Ablation Strategy. J Am Coll Cardiol. 2012;60(19):1921-9. CrossRef PubMed
  9. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, et al. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace. 2012;14(4): 528-606. CrossRef PubMed
  11. Hu YF, Chen YJ, Lin YJ, Chen SA. Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol. 2015;12(4):230-43. CrossRef PubMed
  13. Van Wagoner DR. Oxidative stress and inflammation in atrial fibrillation: role in pathogenesis and potential as a therapeutic target. J Cardiovasc Pharmacol. 2008;52(4):306-13. CrossRef PubMed
  15. Wu G, Cheng M, Huang H, Yang B, Jiang H, Huang C. A variant of IL6R is associated with the recurrence of atrial fibrillation after catheter ablation in a Chinese Han population. PLoS One. 2014;9(6):e99623. CrossRef PubMed PubMedCentral
  17. Martin Aguilar, Xiao Yan Qi, Hai Huang, Philippe Comtois, Stanley Nattel1 Fibroblast Electrical Remodeling in Heart Failure and Potential Effects on Atrial Fibrillation. Biophys J.2014;107:2444–55. CrossRef PubMed PubMedCentral
  19. Wann LS, Curtis AB, Ellenbogen KA, Estes NA, Ezekowitz MD, Jackman WM, et al. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ ESC and 2011 ACCF/AHA/HRS recommendations).
  21. Kalogeropoulos AS, Tsiodras S, Rigopoulos AG, Sakadakis EA, Triantafyllis A, Kremastinos DT, et al. Novel association patterns of cardiac remodeling markers in patients with essential hypertension and atrial fibrillation. BMC Cardiovasc Disord. 2011;11:77. CrossRef PubMed PubMedCentral
  23. Qiu XB, Xu YJ, Li RG, Xu L, Liu X, Fang WY, et al. PITX2C loss-of- function mutations responsible for idiopathic atrial fibrillation. Clinics. 2014;69(1):15-22. CrossRef  
  24. Gramley F, Lorenzen J, Plisiene J, Rakauskas M, Benetis R, Schmid M, et al. Decreased plasminogen activator inhibitor and tissue metallopro- teinase inhibitor expression may promote increased metalloproteinase activity with increasing duration of human atrial fibrillation. J Cardiovasc Electrophysiol. 2007;18(10):1076-82. CrossRef PubMed
  26. Yabluchanskiy A, Ma Y, Chiao YA, Lopez EF, Voorhees AP, Toba H, et al. Cardiac aging is initiated by matrix metalloproteinase-9-mediated endothelial dysfunction. Am J Physiol Heart Circ Physiol. 2014;306(10):H1398-407. CrossRef PubMed PubMedCentral
  28. Z. Hijazi, J. Oldgren, A. Siegbahn, and L. Wallentin Application of Biomarkers for Risk Stratification in Patients with Atrial Fibrillation. Clin Chem. 2017;63(1):152-64. CrossRef PubMed
  30. Huxley RR, Lopez FL, MacLehose RF, Eckfeldt JH, Couper D, Leiendecker-Foster C, et al. Novel association between plasma matrix metalloproteinase-9 and risk of incident atrial fibrillation in a case-cohort study: the Atherosclerosis Risk in Communities study. PLoS One. 2013; 8(3):e59052. CrossRef PubMed PubMedCentral
  32. Li M, Yang G, Xie B, Babu K, Huang C. Changes in matrix metallopro- teinase-9 levels during progression of atrial fibrillation. J Int Med Res. 2014;42(1):224-30. CrossRef PubMed
  34. Fan D, Takawale A, Lee J, et al. Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. Fibrogenesis Tissue Repair. 2012;5:15.
  35. Richter B, Gwechenberger M, Socas A, Zorn G, Albinni S, Marx M, et al. Time course of markers of tissue repair after ablation of atrial fibrillation and their relation to left atrial structural changes and clinical ablation outcome. Int J Cardiol. 2011;152(2):231-6. CrossRef PubMed
  37. Wynn GJ, Das M, Bonnett LJ, Panikker S, Wong T, Gupta D. Efficacy of catheter ablation for persistent atrial fibrillation: a systematic review and meta-analysis of evidence from randomized and nonrandomized controlled trials. Circ Arrhythm Electrophysiol. 2014;7(5):841-52. CrossRef PubMed
  39. Sramko M, Peichl P, Wichterle D, Tintera J, Weichet J, Maxian R, et al. Clinical value of assessment of left atrial late gadolinium enhancement in patients undergoing ablation of atrial fibrillation. Int J Cardiol. 2015;179: 351-7. CrossRef PubMed
  41. Lewkowicz J, Knapp M, Tankiewicz-Kwedlo A, Sawicki R, Kaminska M, Waszkiewicz E, et al. MMP-9 in atrial remodeling in patients with atrial fibrillation. Ann Cardiol Angeiol (Paris). 2015.
  43. Kato K, Fujimaki T, Yoshida T, et al. Impact of matrix metalloproteinase-2 levels on long-term outcome following pharmacological or electrical cardioversion in patients with atrial fibrillation. Europace. 2009; 11: 332–7. CrossRef PubMed
  45. Lombardi F, Belletti S, Battezzati PM, Pacciolla R, Biondi ML. MMP-1 and MMP-3 polymorphism and arrhythmia recurrence after electrical cardiover- sion in patients with persistent atrial fibrillation. J Cardiovasc Med (Hagerstown). 2011;12(1):37-42. CrossRef PubMed
  47. Cerisano G, Buonamici P, Gori AM, Valenti R, Sciagra R, Giusti B, et al. Matrix metalloproteinases and their tissue inhibitor after reperfused ST- elevation myocardial infarction treated with doxycycline. Insights from the TIPTOP trial. Int J Cardiol. 2015;197:147-53. CrossRef PubMed
  49. Hirsh BJ, Copeland-Halperin RS, Halperin JL. Fibrotic atrial cardiomyo- pathy, atrial fibrillation, and thromboembolism: mechanistic links and clinical inferences. J Am Coll Cardiol. 2015;65(20):2239-51. CrossRef PubMed

© National Academy of Sciences of Ukraine, Bogomoletz Institute of Physiology, 2014-2024.